M&A Deal Summary

Johnson & Johnson Acquires Proteologix

On May 16, 2024, Johnson & Johnson acquired life science company Proteologix for 850M USD

Acquisition Highlights
  • This is Johnson & Johnson’s 18th transaction in the Life Science sector.
  • This is Johnson & Johnson’s 20th largest (disclosed) transaction.
  • This is Johnson & Johnson’s 37th transaction in the United States.
  • This is Johnson & Johnson’s 16th transaction in California.

M&A Deal Summary
Date 2024-05-16
Target Proteologix
Sector Life Science
Buyer(s) Johnson & Johnson
Deal Type Add-on Acquisition
Deal Value 850M USD

Target

Proteologix

California, United States
Proteologix is a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases. The company's portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. Proteologix is based in California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Johnson & Johnson

New Brunswick, New Jersey, United States
Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 85.2B USD (2023)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 44 of 45
Sector (Life Science) 18 of 18
Type (Add-on Acquisition) 35 of 36
State (California) 16 of 16
Country (United States) 37 of 37
Year (2024) 3 of 4
Size (of disclosed) 20 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-05 ShockWave Medical

Santa Clara, California, United States

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ShockWave Medical was founded in 2009 and is based in Santa Clara, California.

Buy $13.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-09 V-Wave

Caesarea, Israel

V-Wave develops percutaneous implantable technologies for patients with chronic heart failure. V-Wave was formed in 2009 and is headquartered in Caesarea, Israel.

Buy -
Mergr

Product

Company

Legal